Researching Rise Regenerative Medicine? A 2026 Vetting Guide

Introduction: Searching a Clinic Name Is Only the First Step

People who type “Rise Regenerative Medicine” into a search engine are rarely looking only for a phone number. Many are in the research phase, comparing options, checking credentials, and deciding whether a regenerative treatment is worth the time, money, and risk before booking.

This guide is independent and provider-agnostic. TopDoctor Magazine is not affiliated with, endorsed by, or representing Rise Regenerative Medicine or any other specific clinic. Nothing here is a recommendation for or against any provider.

The problem with most search results is simple. Local directories list facts such as pricing, hours, and service menus, but they offer no way to judge legitimacy. Generic “red flag” articles offer a framework but no local specificity. This guide connects the two. It provides a reusable due-diligence checklist covering ownership structure, FDA and HCT/P status, exosome red flags, pricing benchmarks, and informed consent. The checklist applies to Rise, to its Seattle-area alternatives, and to any regenerative practice nationwide.

The stakes are significant. The global regenerative medicine market is estimated at roughly $48 billion in 2026 and is growing quickly, with North America holding about 43% of that market in 2025. A commercial environment of that size rewards both excellent providers and aggressive marketers, making careful research essential for patients.

What Naturopathic-Led Regenerative Clinics Typically Offer

Rise Regenerative Medicine is a Seattle clinic led by Dr. Sierra Storm, who is described as a Naturopathic Physician and Sports Medicine Anti-Aging Specialist. The practice focuses on pain care, scar therapy, facial rejuvenation, and hair restoration. Its menu is typical of naturopathic-led regenerative clinics, which commonly offer:

• PRP (platelet-rich plasma) injections
• Prolotherapy
• Trigger point injection therapy
• Scar therapy
• Hyperbaric oxygen therapy (HBOT)
• Hormone balancing
• Gut and food-sensitivity testing
• Peptide and GLP-1 programs

The provider’s credential matters. Naturopathic physicians are licensed in some states, including Washington, and their scope of practice is set by state law. That scope differs from the scope of MD- or DO-led orthopedic or sports medicine practices, which may perform surgery, order a wider range of imaging, or administer certain biologics under different oversight structures. Neither model is automatically better; patients should simply understand which model they are entering.

These clinics generally provide non-invasive, injection-based therapies rather than surgical stem cell or exosome procedures. That distinction affects both risk level and regulatory classification. Even so, every service category above has specific points a patient should verify independently before scheduling or paying for treatment.

Step 1: Determine Who Actually Owns and Directs the Clinic

Ownership shapes incentives. A practice owned and directed by physicians makes clinical decisions differently from an investor-backed or private-equity rollup, where pressure around patient volume and upselling can influence recommendations.

The most direct question to ask is: “Is this clinic owned and directed by physicians, or by investors and business executives?”

Patients can also research this independently:

1. State business registries list registered owners, officers, and agents for the business entity.
2. LinkedIn leadership searches can reveal whether executives come from clinical or financial backgrounds.
3. State medical and naturopathic board lookups confirm which licensed providers are tied to the practice.
4. The clinic’s “About” page, checked against public records, should tell a consistent story.

For naturopathic-led clinics, the practice should be able to state clearly which licensed provider oversees each type of procedure and whether that provider is present on-site during treatment.

Step 2: Decode FDA and HCT/P Regulatory Status

One fact every patient should know: as of 2026, no regenerative medicine product, including stem cells, amniotic fluid, or umbilical cord-derived material, is FDA-approved for treating orthopedic conditions such as back pain. This applies broadly to joint and orthopedic claims made by regenerative clinics across the country.

Confusion often comes from the term “361 product.” Many clinics describe injectable biologics as “FDA compliant” or “FDA registered.” Usually, this means the product meets minimal-manipulation criteria under 21 CFR Part 1271, the federal regulation governing human cells, tissues, and cellular and tissue-based products (HCT/Ps). It does not mean the product is an FDA-approved drug.

The FDA has been explicit that stem cell products are regulated by the agency and generally require FDA approval. Yet clinics too often claim their products are “FDA approved” when, at best, what they sell is technically compliant with the rules for 361 products. Any claim of FDA approval should be verified.

The risks are documented. In its patient and consumer warning, the FDA states that it continues to receive reports of adverse events, including patient deaths, following use of unapproved products made from human cells or tissues. A Pew analysis found more than 360 reported cases of serious side effects from unproven stem cell procedures between 2004 and September 2020.

A simple script for the consultation: “Is this product regulated as a 361 HCT/P, or does it require separate FDA approval, and can you show me documentation of that status?”

Step 3: Watch for Exosome Marketing Red Flags (2026’s Regulatory Flashpoint)

Exosomes are the current enforcement priority. There are zero FDA-approved exosome products for any medical use, yet some clinics market them aggressively as “stem cell therapy without the cells.”

The enforcement activity is active, not theoretical:

• In August 2026, the FDA issued a warning letter to R3 Medical Companies citing unapproved stem cell and exosome products along with CGMP (current good manufacturing practice) violations.
• In the first quarter of 2026 alone, the FDA issued warning letters to clinics in Florida, California, and Texas for marketing unapproved exosome products.

A common misconception needs correcting. Calling a product an “exosome” does not exempt it from HCT/P regulation, and most exosome products do not meet the FDA’s criteria for minimal manipulation.

Red-flag phrasing in marketing materials includes:

• “Cell-free regeneration”
• “Next-generation stem cell alternative”
• Vague sourcing language that avoids naming the manufacturer or the processing method

Step 4: Benchmark Pricing and Demand Transparency

National ranges give patients a way to sanity-check quotes:

Treatment	Typical National Range
PRP injection	$500 to $2,500 per session
Stem cell therapy	$5,000 to $50,000

For the clinic in this search, third-party directories list a GLP-1 program priced at $62.50 per weekly visit with two peptide compounds offered (BPC-157 and Semaglutide). That places the practice in the lower-to-mid range of menu depth compared with 10 or more other Washington peptide clinics in those listings. Menu depth is not a quality measure in itself, but it shows how directories benchmark clinics.

Published, itemized pricing is a positive signal. Directory research notes that Seattle regenerative clinics publishing prices upfront are the exception rather than the norm.

Transparency red flags include:

• Cash-only payment demanded before any consultation
• Refusal to itemize costs per procedure
• Bundled “packages” that hide per-session pricing
• High-pressure, same-day sales tactics

Step 5: Review Informed Consent and Documentation Standards

Legitimate informed consent should disclose:

• The source of the cells or product
• The processing method
• Regulatory status
• Realistic success-rate expectations
• Documented risks

Clinical and legal sources consistently identify these warning signs:

• Missing physician involvement, such as sales staff making treatment recommendations instead of licensed providers
• No written informed consent
• No scheduled follow-up plan
• Refusal to disclose cell source, processing method, or regulatory status

Some claims are red flags regardless of clinic type:

• Guaranteed or “100% success” language
• The same protocol marketed for unrelated conditions, such as one injection promoted for both joint pain and anti-aging
• Non-physician staff performing injection procedures without appropriate licensure

Patients should request a copy of the consent form before the appointment, not only at the point of treatment, so they have time to read it carefully.

Step 6: Build Your Independent Verification Toolkit

Several free, authoritative tools allow patients to check a clinic’s claims:

• FDA Warning Letter Database. Searchable by clinic or company name, it shows prior enforcement actions. The FDA’s Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes, available on FDA.gov, explains why these products generally require approval.
• ClinicalTrials.gov. Patients can check whether a treatment protocol is tied to a registered trial. Study NCT04711551, which assesses outcomes in patients undergoing regenerative treatments with orthobiologics, is a model of what registry-based, research-backed care looks like.
• State medical and naturopathic licensing boards. These confirm a provider’s license status, disciplinary history, and scope of practice.
• The ISSCR Guide to Stem Cell Treatments. Published by the International Society for Stem Cell Research, this is the leading independent, non-commercial patient resource. It warns that unproven stem cell “treatments” are marketed by unscrupulous clinics worldwide and is designed to help patients evaluate claims before committing.
• FTC enforcement actions. This is a secondary check for clinics cited over deceptive marketing claims, separate from the FDA’s product-safety jurisdiction.

Putting It Together: A Provider-Agnostic Vetting Checklist

Patients can print or save this pre-consultation checklist:

1. Ownership and credentials: Who owns the clinic? Which licensed provider oversees each procedure, and are they on-site?
2. FDA and HCT/P status: Is the product a 361 HCT/P or does it require FDA approval? Is documentation available?
3. Exosome scrutiny: Are exosomes offered? Who manufactures them, and how are they processed?
4. Itemized pricing: Are per-session costs published or provided in writing?
5. Written informed consent: Can the form be reviewed in advance? Does it cover source, processing, status, risks, and realistic outcomes?
6. Independent database checks: Has the clinic appeared in FDA warning letters or FTC actions? Are providers in good standing with their state board?

Each question should be asked during an initial consultation, before any treatment is agreed upon or payment is made.

How a clinic responds is itself information. Legitimate, well-run practices welcome direct questions about regulatory status and sourcing. Evasive, dismissive, or rushed answers are a red flag.

This checklist applies equally to Rise Regenerative Medicine, to another Seattle-area provider, or to any regenerative clinic found through search or referral.

Conclusion: Evaluation Before Booking Protects Patients and Their Investment

Brand reputation and polished marketing are not enough. Informed, independent due diligence is what separates a well-regulated, physician-informed regenerative practice from one that is legal but unproven.

The six-step framework is reusable. It works no matter which clinic a patient is considering. Because the field is evolving quickly, and because 2026 enforcement trends around exosomes show how fast the regulatory picture can shift, verification should be ongoing rather than a one-time check.

In a fast-growing and loosely regulated market, informed patients remain the most effective check on questionable practices.

Keep Researching Before Booking: Further Resources

Before scheduling any consultation, patients should bookmark and consult the primary sources referenced in this guide: the FDA’s consumer alerts and warning letter database on FDA.gov, the ISSCR patient guide on ISSCR.org, and ClinicalTrials.gov.

TopDoctor Magazine’s broader editorial coverage of regenerative, functional, and integrative medicine offers ongoing provider education and in-depth interviews with practitioners in the field. Readers can also subscribe to the free TopDoctor Magazine newsletter for continued coverage of regulatory developments, provider vetting guides, and emerging categories such as peptide therapy and exosome regulation.

Disclaimer: TopDoctor Magazine is not affiliated with, endorsed by, or representing Rise Regenerative Medicine or any clinic mentioned in this article. This guide is for educational purposes only and is not medical advice. Patients should consult a qualified, licensed healthcare provider before beginning any treatment.